Patents by Inventor Fotios PLAKOGIANNIS

Fotios PLAKOGIANNIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11975112
    Abstract: Compositions, devices, and methods for transdermal administration of olanzapine and uses thereof, e.g., to treat nausea and vomiting.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: May 7, 2024
    Assignee: Starton Therapeutics, Inc.
    Inventors: James Oliver, Fotios Plakogiannis, Tamanna Lather, Marina Borovinskaya, Nisarg Modi, Rod L. Hartwig
  • Publication number: 20240009204
    Abstract: Kits, compositions, devices, and methods for administration of olanzapine are provided. Uses thereof to treat nausea and vomiting are also provided.
    Type: Application
    Filed: September 24, 2021
    Publication date: January 11, 2024
    Inventors: James Oliver, Fotios Plakogiannis, Tamanna Lather, Marina Borovinskaya, Nisarg Modi, Rod L. Hartwig, Yuliya Levintova
  • Publication number: 20220395468
    Abstract: Transdermal drug delivery systems and methods of fabricating such systems are provided. The active pharmaceutical ingredient can be lenalidomide or other immunomodulatory agents. More particularly, the present invention is directed to improving the solubility of lenalidomide and other immunomodulatory imide compounds and improving the permeation of such compounds through the skin.
    Type: Application
    Filed: June 3, 2022
    Publication date: December 15, 2022
    Inventors: Fotios Plakogiannis, Rod L. Hartwig, Nisarg Modi, Tamanna Lather, Yuliya Levintova, Marina Borovinskaya, Arturo Serrano-Batista
  • Publication number: 20220054473
    Abstract: Provided are systems and methods for continuously administering to a subject in need of treatment a formulation comprising an immunomodulatory imide compound. In some embodiments, the method are for use in treating multiple myeloma, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Inventors: Marina Borovinskaya, Fotios Plakogiannis, Nisarg Modi, Tamanna Lather, Rod L. Hartwig, James C. Oliver
  • Publication number: 20220040194
    Abstract: The present invention generally relates to a combination therapy of a PARP-inhibitor and olanzapine. More particularly, embodiments relate to a method of administering to a patient one or more of a PARP-inhibitor in a therapeutic amount to a patient in need thereof, and olanzapine, in a sufficient amount to treat or alleviate PARP-inhibitor induced nausea or vomiting. In embodiments, the PARP-inhibitor and olanzapine are administered in a common administration schedule. In some embodiments, both actives are orally administered. In other embodiments, olanzapine is transdermally administered. In certain embodiments, the PARP-inhibitor is one or more of olaparib, rucaparib, and niraparib.
    Type: Application
    Filed: December 17, 2019
    Publication date: February 10, 2022
    Inventors: Pedro Lichtinger Waisman, Cidnee Vaykovich, Fotios Plakogiannis
  • Patent number: 11197852
    Abstract: Provided are methods for continuously administering to a subject in need of treatment a formulation comprising an immunomodulatory imide compound. In some embodiments, the method are for use in treating multiple myeloma, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: December 14, 2021
    Assignee: Starton Therapeutics, Inc.
    Inventors: Marina Borovinskaya, Fotios Plakogiannis, Nisarg Modi, Tamanna Lather, Rod L. Hartwig, James C. Oliver, Yuliya Levintova
  • Publication number: 20210244679
    Abstract: Compositions, devices, and methods for transdermal administration of olanzapine and uses thereof, e.g., to treat nausea and vomiting.
    Type: Application
    Filed: January 13, 2021
    Publication date: August 12, 2021
    Inventors: James Oliver, Fotios Plakogiannis, Tamanna Lather, Marina Borovinskaya, Nisarg Modi
  • Publication number: 20200330445
    Abstract: Provided are methods for continuously administering to a subject in need of treatment a formulation comprising an immunomodulatory imide compound. In some embodiments, the method are for use in treating multiple myeloma, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.
    Type: Application
    Filed: April 21, 2020
    Publication date: October 22, 2020
    Inventors: Marina BOROVINSKAYA, Fotios PLAKOGIANNIS, Nisarg MODI, Tamanna LATHER, Rod L. Hartwig, James C. OLIVER